Guardant Health, Inc. (GH) Stock

About Guardant Health, Inc.

Guardant Health, Inc. is led by CEO Helmy Eltoukhy, employs 2,506 people, headquartered in Palo Alto, US, publicly traded since 2018.

Guardant Health, Inc. (GH) stock trades at $165.56 with a market capitalization of $22.22B. The stock is valued at a price-to-earnings (P/E) ratio of -48.23, price-to-book of -99.75, price-to-sales of 19.09. Over the past 52 weeks the stock has ranged between $61.00 and $191.05, and currently trades 13.3% below its 52-week high.

On profitability, Guardant Health, Inc. generates a return on equity (ROE) of 211.46% — well above the market average, a sign of a high-quality business, return on capital employed of -29.89%, an operating margin of -41.43%, a net profit margin of -38.33%.

In its most recent fiscal year, Guardant Health, Inc. reported annual revenue of $982.0M, net profit of $-416.0M, revenue has compounded at 27.9% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of -7.61 — a conservative balance sheet with little leverage risk, a current ratio of 4.84, total assets of $2.0B, $378.0M in cash and equivalents.

GH has an average daily trading volume of 2,366,420 shares, a beta of 1.58 (more volatile than the overall market).